novabay_8k-101012.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of earliest event reported: October 10, 2012
NovaBay Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
001-33678
|
68-0454536
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
5980 Horton Street, Suite 550, Emeryville, CA 94608
(Address of Principal Executive Offices) (Zip Code)
(510) 899-8800
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 23, 2012, NovaBay Pharmaceuticals, Inc. filed a Current Report on Form 8-K reporting that on February 17, 2012, the Compensation Committee of the Board of Directors of NovaBay established bonuses for NovaBay’s executive officers for performance in 2011, and that (a) it paid only 70% of the bonus amount at that time, and in stock options in lieu of cash, and (b) the remaining 30% of the bonus would be paid later in the year or early in the following year, either in the form of stock options or cash, as determined by the Compensation Committee. On October 10, 2012, the Board of Directors of NovaBay determined to pay the remaining 30% of the bonuses in cash, plus an additional 4% to compensate the officers for the delay in payment, as follows:
|
Name
|
Title
|
|
Remaining
Bonus
Amount
|
|
|
Ramin (“Ron”) Najafi, Ph.D.
|
Chairman and Chief Executive Officer
|
|
$
|
33,290
|
|
|
Thomas J. Paulson
|
Chief Financial Officer and Treasurer
|
|
$
|
18,844
|
|
|
Behzad Khosrovi, Ph.D.
|
Chief Alliance Officer and SVP, Product Development
|
|
$
|
17,939
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
NovaBay Pharmaceuticals, Inc.
|
|
| |
(Registrant) |
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
|
|
By:
|
/s/ Thomas J. Paulson |
|
| |
|
Thomas J. Paulson
|
|
| |
|
Chief Financial Officer and Treasurer
|
|
Dated: October 16, 2012